@article{ribrag:hal-01068681,
TITLE = {A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma},
AUTHOR = {Ribrag, Vincent and Dupuis, Jehan and Tilly, Herve and Morschhauser, Franck and Laine, Fabrice and Houot, Roch and Haioun, Corinne and Copie, Christiane and Varga, Andrea and Lambert, John and Hatteville, Laurence and Ziti-Ljajic, Samira and Caron, Anne and Payrard, Sandrine and Coiffier, Bertrand},
URL = {https://hal.science/hal-01068681},
JOURNAL = {Clinical Cancer Research},
PUBLISHER = {American Association for Cancer Research},
VOLUME = {20},
NUMBER = {1},
PAGES = {213--220},
YEAR = {2014},
DOI = {10.1158/1078-0432.CCR-13-0580},
KEYWORDS = {Adult ; Aged ; 80 and over ; Antibodies ; Monoclonal ; Humanized ; Antineoplastic Agents ; Asthenia ; Drug Resistance ; Neoplasm ; Female ; Lymphoma ; B-Cell ; Middle Aged ; Maytansine ; Maximum Tolerated Dose ; Male ; Infusions ; Neoplasm Recurrence ; Local ; Treatment Outcome ; Intravenous ; Liver ; Kidney ; Humans},
HAL_ID = {hal-01068681},
HAL_VERSION = {v1},
}